Biomind Labs Inc. OTC Markets

CRSWF

CA0907021012

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:14:29 04/04/2024 BST			5-day change	1st Jan Change
0.11 ^USD	-.--%		-.--%	-89.00%

2023	Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	CI
2023	Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Crosswinds Holdings Inc. Announces Executive Changes

July 23, 2018 at 10:40 pm

Crosswinds Holdings Inc. announced that it has given working notice of termination to Colin King, its Chief Executive Officer, and to Helen Martin, its Chief Operating Officer.

Latest news about Biomind Labs Inc.

Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	14/09/23	CI
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
An unknown buyer acquired 27.09% stake in Biomind Labs Inc. (OTCPK:BMND.F) from Union Acquisition Group, LLC for $14.1 million.	26/04/23	CI
Biomind Labs Inc. Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’S Disease with A Proprietary Formulation Based on 5-Meo-Dmt	25/04/23	CI
Biomind Labs Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s Disease	28/12/22	CI
Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression	15/11/22	CI
Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant Depression	04/11/22	CI
Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant Depression	11/10/22	CI
Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery System	27/09/22	CI
Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant Depression	21/09/22	CI
Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease	26/05/22	CI
Crosswinds Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	15/05/22	CI
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	15/05/22	CI
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression	26/04/22	CI
Biomind Labs Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	01/04/22	CI
Biomind Labs to Commence Commercial Clinical Trial on Its Proprietary Mescaline Candidate BMND06	24/03/22	CI
Biomind Labs Opens a New Clinical Psychedelic Research Facility	17/03/22	CI
Biomind Labs Inc. Receives Approval for a Second Phase II Clinical Trial for Treatment-resistant Depression	09/03/22	CI
Biomind Labs Inc. Announces Positive Results on in Vivo Studies for its Proprietary Drug Candidate BMND07	03/03/22	CI
Biomind Labs Inc. Announces Design of a Pharmaceutical Form for Psychedelic Drug Delivery Using 3D Printing	24/11/21	CI
Biomind Labs Inc. Completes Development of A Thermosensitive Nasal Gel Pharmaceutical Dosage Form	18/11/21	CI
Biomind Labs Files International Patent Application on its DMT Candidates Across 153 Global Jurisdictions	28/09/21	CI
Biomind Labs Inc. to Advance A Phase II Clinical Trial on DMT for Treatment-Resistant Depression	18/08/21	CI
Biomind Gets Approval in Brazil for Phase 2 DMT Depression Trial	18/08/21	DJ

Biomind Labs Inc. is a Canada-based biotech research and development company. The Company is primarily engaged in biotech platform that integrates biology, chemistry, medicine, neuroscience, technology, intellectual property and pharma grade production with special focus on scientific research, clinical trials and in jurisdictions that open a fast track in the molecule to market lifecycle. Through its acceleration platform, it is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (DMT), 5-MeO-DMT, and mescaline for treating a range of therapeutic indications. 5-MeO-DMT is a powerful psychedelic tryptamine. Under the 5-MeO-DMT Program, the Company is focused on two drug candidates: BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and BMND08: 5-MeO-DMT novel formulation indicated for Alzheimerâs disease. Mescaline is a psychedelic alkaloid of the phenethylamine class. DMT Program is a serotonergic psychedelic.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+44.98%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B